Modality
ASO
MOA
WEE1i
Target
IL-17A
Pathway
Apoptosis
RBMeso
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
Sep 2017
→ Jan 2029
Phase 2Current
NCT03774626
1,774 pts·Meso
2024-12→2029-01·Active
NCT06684870
516 pts·Meso
2017-09→2028-04·Not yet recruiting
2,290 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-06-193mo awayNDA· RB
2028-04-042.0y awayPh3 Readout· Meso
2029-01-132.8y awayPh3 Readout· Meso
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Not yet…
P2/3
Active
Catalysts
NDA
2026-06-19 · 3mo away
RB
Ph3 Readout
2028-04-04 · 2.0y away
Meso
Ph3 Readout
2029-01-13 · 2.8y away
Meso
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03774626 | Phase 2/3 | Meso | Active | 1774 | PFS |
| NCT06684870 | Phase 2/3 | Meso | Not yet recr... | 516 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| MDG-611 | Madrigal Pharma | Approved | CGRP |